Skip to main content
CStone Pharmaceuticals logo

CStone Pharmaceuticals — Investor Relations & Filings

Ticker · 2616 ISIN · KYG2588M1006 LEI · 300300095A57F80T2461 HKEX Manufacturing
Open in API
Filings indexed 3,371 across all filing types
Latest filing 2025-04-17 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 2616

About CStone Pharmaceuticals

http://www.cstonepharma.com

CStone Pharmaceuticals is an innovation-driven biopharmaceutical company focused on the research, development, and commercialization of anti-tumor drugs. The company is dedicated to addressing the unmet medical needs of cancer patients globally. Its core therapeutic focus is on innovative immuno-oncology and molecularly targeted therapies. The R&D pipeline is strategically balanced, featuring potential first-in-class or best-in-class assets, including Antibody-Drug Conjugates (ADC) and multi-specific antibodies. CStone has successfully launched four innovative drugs and secured multiple New Drug Application and indication approvals.

Recent filings

Filing Released Lang Actions
ANNOUNCEMENT ON THE MAJOR OPERATIONAL DATA FOR THE FIRST QUARTER OF 2025
Regulatory Filings Classification · 1% confidence The document is a voluntary announcement by Yankuang Energy Group providing operational data (production and sales volumes) for Q1 2025. It does not contain financial statements or profit/loss figures, nor does it announce dividends, board changes, financing, or legal matters. It is not a full interim or annual report, call transcript, or proxy solicitation; rather, it is a standalone operational update published under listing rules. Thus it falls into the general "Regulatory Filings" fallback category (RNS).
2025-04-17 English
(I) GRANT OF RESTRICTED SHARE UNITS UNDER THE POST-IPO RSU SCHEME&#x3b; AND (II) GRANT OF SHARE OPTIONS UNDER THE POST-IPO ESOP
Share Issue/Capital Change Classification · 1% confidence The document is a Hong Kong Exchange announcement under Listing Rules 17.06A–C disclosing the Board’s resolution to grant restricted share units (RSUs) and share options (ESOP) to employees and a director under post-IPO incentive schemes. This is not an earnings release, a legal update, or a management discussion, nor is it a simple report publication. It details the grant of equity-linked instruments which will result in the issuance of new shares upon exercise or vesting. According to the filing taxonomy, announcements concerning new share issues, option grants, and other capital changes are classified as Share Issue/Capital Change (SHA).
2025-04-11 English
NEXT DAY DISCLOSURE RETURN
Share Issue/Capital Change Classification · 1% confidence The document is a Next Day Disclosure Return (Form FF305) filed under Hong Kong Exchange listing rules to report changes in issued shares or treasury shares. It details the allotment and issue of new shares under a placing agreement, with share numbers and prices. This is not a full annual report or interim report but a specific announcement of capital change (new share issue and treasury share transactions). Therefore, it fits the “Share Issue/Capital Change” category.
2025-04-10 English
COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE
Share Issue/Capital Change Classification · 1% confidence The document is an announcement by CStone Pharmaceuticals about the completion of a placing of 80,000,000 new shares under a general mandate, including shareholding structure changes and use of proceeds. This clearly describes the issuance of new shares and a change in the company’s capital. Therefore, it falls under the “Share Issue/Capital Change” category.
2025-04-10 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 1% confidence The document is a short announcement (under 5,000 characters) notifying shareholders of a board meeting date and agenda to consider the publication of first quarter results. It is not the results themselves (so not an IR report), nor is it a direct report publication with attachments or links (so not an RPA). It does not involve board composition changes, financing, dividends, or other specific categories. Therefore it falls under a general regulatory announcement that does not fit more specific types: RNS.
2025-04-10 English
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
Regulatory Filings Classification · 1% confidence The document is extremely short (242 characters) and serves as a notification that an announcement has been published elsewhere on the website. It does not contain financial data, meeting details, or specific corporate actions, but rather acts as a pointer to another document. Per the 'Menu vs Meal' rule, this is a Report Publication Announcement.
2025-04-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.